Xsolla Expands Support for Game Developers Through the Greater China Region Launch, Marking a New Era in the Gaming Industry
22.7.2024 15:00:00 EEST | Business Wire | Press release
Xsolla, a global video game commerce company known for its extensive suite of tools and services specifically designed for the game industry, is thrilled to announce the grand opening of the Xsolla Greater China Region office. The opening event will occur on Monday, July 22, 2024, at D-06 Parkview Green Fangcaodi, Chaoyang District, signifying a renewed commitment to enhancing and growing the video game industry in China and worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722568214/en/
(Graphic: Xsolla)
The expansion of the Xsolla Beijing office embodies a vision to serve as a humble partner and provide access to the tools and services for everyone in the gaming community, assisting companies with ambitions to navigate and reach emerging markets swiftly. This expansion is not just a physical establishment; it is the center of China's technology and gaming community.
Under the theme "Equal Access for Everyone," the opening ceremony is expected to gather industry leaders, esteemed partners, and media representatives to witness the unveiling of a new chapter that promises to bring forth opportunities, foster talent, and encourage the creation of groundbreaking gaming experiences. The event will feature various performances and interactive sessions designed to encapsulate the spirit of exploration and the limitless potential of the gaming industry.
A highlight of the ceremony will be introducing specialized programs and partnerships to bolster the growth of the gaming ecosystem in China, which is extended by geographical borders. These initiatives include strategic collaborations with key platforms and creators to provide comprehensive marketing support, enhance game development, and optimize monetization strategies, laying the groundwork for Chinese games to thrive globally.
Jingbo Chen, Head of the Greater China Region, will share insights on Xsolla's strategic goals and visions for the market. "The opening of our office in Beijing marks a pivotal step in Xsolla's journey to facilitate the global expansion of games created and developed in China. Our commitment is to be the cornerstone for developers and publishers, offering them a gateway to explore and excel in international markets," stated Jingbo.
Berkley Egenes, Chief Marketing Officer and Chief Growth Officer of Xsolla, added, "The establishment of our Beijing office is a testament to our belief in the potential of local game developers and their creations on the global stage. By fostering closer collaborations and providing direct support, we are excited to play a part in showcasing China's gaming innovation to the world. This initiative underscores our dedication to empowering the gaming community, ensuring our partners have the tools and resources to succeed in an increasingly competitive market."
Stay tuned for more updates, and follow Xsolla on WeChat to stay updated on the Greater China Region's endeavors and upcoming projects. Follow and get involved in the discussion at:
For further information about Xsolla and its initiatives in the Greater China Region, please visit - xsolla.com/zh
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Beijing, Guangzhou, Seoul, Tokyo, Kuala Lumpur, Raleigh, and cities around the world, Xsolla supports major gaming titles like Valve, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240722568214/en/
Contacts
Media Contact
Derrick Stembridge
Global Director of Public Relations, Xsolla
d.stembridge@xsolla.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 12:52:00 EEST | Press release
The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not merely a wage dispute. It stems from deep structural concerns regarding the company’s ESG management, lack of operational autonomy, and passive labor relations. Primarily, the union highlighted unresolved corporate governance issues, including allegations concerning unfair labor practices and the unauthorized use of employee personal data, which were prominently reported by South Korea's major broadcaster, MBC, in November 2025. The union believes this crisis stems from management's failure to address r
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 12:00:00 EEST | Press release
The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that elevates high-performance riders and horses to their rightful place on the world stage. Built on merit, integrity, and excellence, the PJL brings together the world’s best athletes to compete for the biggest prize pot in the discipline’s history, helping to create a more resilient, long-term financial model for the sport. Represented by sixteen teams, the PJL will introduce an industry-first rider selection process from a pool of 250 of the world’s leading riders. World-class, immersive events will unfold across fourteen ic
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 12:00:00 EEST | Press release
Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkbj) for the treatment of spastic cerebral palsy (CP). On top of safety and tolerability, the study will evaluate improvements in daily functioning, quality of life, motor abilities, and neurodevelopmental measures of the Cenegermin-bkbj intranasal formulation. CP is the most common motor disability in childhood, caused by injury or changes during early brain development. The most prevalent form, spastic CP, leads to muscle stiffness and difficulty with movement.2 “Cerebral palsy is a devastating disease, and for patients and families there are still no proven treatments beyond supportive care,” said Marcello Allegretti, Chief Scientific Officer at Dompé. “With our emerging intranasal NGF p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom